Study reveals that 79% of RA patients would prefer oral tablet treatment
Pfizer and Research Partnership presented the poster “Patient preferences for oral versus injectable and intravenous methods for Rheumatoid Arthritis” at ISPOR 16th Annual European Congress, 2-6 November in Dublin.
The poster, co-authored by Director Sue Marett and Research Manager Nicky Barclay, investigated RA patient administration preferences utilising data from a recent study conducted by Research Partnership for Pfizer.
Mike Mallinson joins the Access Partnership
Mike Mallinson has been appointed to lead the Access Partnership in the role of President.
Mike is a highly regarded pharma executive with over 30 years experience gained both agency and client-side, who has presented and published opinion papers on market access issues at many international meetings. Mike is supported by Rob White, Global Director of Market Access and Dr Shrinivas Rao Mukku, Global Director of Pricing and Reimbursement.Commenting on his appointment, Mike said, “I am delighted to be taking on this challenging new position. Our aim is for the Access Partnership to become the preferred commercial partner for delivering market access solutions, by gaining a reputation for delivering the best payer and key stakeholder insights and outstanding strategic consulting services. We recognise the access challenges facing our clients, particularly across the Tier 1 and Tier 2 Emerging Markets - having an Asia Pacific presence will mean we are well placed to meet our clients’ needs in this region.”The Access Partnership will be attending and exhibiting at ISPOR’s (International Society for Pharmacoeconomics and Outcomes Research) Annual European Congress at the ICC in Berlin 5-7 November, where they will be giving two podium and two poster presentations. Delegates are able to visit them on Stand 34 of the exhibition. Sign up to receive Rapport Rapport is our…
Announcing a new strategic market access consultancy
The Research Partnership is today launching a new market access consultancy called "The Access Partnership" which will provide services to the pharmaceutical, biotech and medtech industries.
The Access Partnership will work with manufacturers to help them develop the value strategy for their technologies, including pricing, market access and payer engagement, in order to achieve commercial success for their innovations. The company’s global headquarters are based in London, UK, with other offices in the US and Singapore.The company has also made two senior appointments. Rob White joins as Global Director of Market Access and Dr Shrinivas Rao Mukku joins as Global Director of Pricing and Reimbursement.Rob White (shown above) has over 20 years experience within the pharma industry at Sanofi Aventis and MSD leading on a number of roles including delivering market access strategies and tools to support brands in key areas such as diabetes, HIV, oncology, cardiovascular as well as the device space. Rob has developed an extensive payer network which he has used to help clients deliver relevant payer value propositions and support segmentation across the EU and US markets. Rob has also delivered training for pharma KAM teams and supported teams with contract negotiations and the development of business cases to drive brand market access.Shrinivas Rao Mukku has 18 years of research management, training and consultancy experience in Europe and South East Asia. In…